• IMA sites
  • IMAJ services
  • IMA journals
  • Doctors card
  • Follow us
  • Alternate Text Alternate Text
עמוד בית
Wed, 29.06.22

Original Articles


Assessing the Effectiveness of Dead Sea Products as Prophylactic Agents for Acute Radiochemotherapy Induced Skin and Mucosal Toxicity in Patients with Head and Neck Cancers: A Phase 2 study

Click on the icon on the upper right hand side for the article by Diana Matceyevsky, MD, Neora Yaal Hahoshen, MD, Akiva Vexler, MD, PhD, Noam Asna, MD, Avi Khafif, MD and Rami Ben-Yosef, MD, Division of Oncology and Department of Otolaryngology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
IMAJ 2007: 9: June: 439-442
Abstract

Background: Mucositis and dermatitis are frequently encountered in patients treated with radiochemotherapy. Dead Sea products that contain minerals and different substances have proved effective in treating various skin diseases.


Objectives: To evaluate the effectiveness of Dead Sea products in reducing acute radiochemotherapy‑induced side effects in patients with head and neck cancer.


Methods: In this phase 2 study we compared the outcomes in 24 treated patients and 30 conventionally treated patients matched for age, tumor site, and type of treatment. The Dead Sea products comprised a mouthwash solution (Lenom®) and a skin cream (Solaris®) used three times daily for 1 week before, during, and up to 2 weeks after completion of radiotherapy. Mucositis and dermatitis were evaluated using common toxicity criteria.


Results: Thirteen treated patients (54%) had grade 1-2 and none had 3-4 mucositis, while 17 controls (57%) had grade 1-2 and 4 (13%) had grade 3-4 mucositis. Thirteen treated patients (54%) had grade 1-2 dermatitis; there was no instance of grade 3-4 dermatitis, while 11 patients in the control group (37%) had grade 1-2 and 5 (17%) had grade 3-4 dermatitis. More patients in the control arm needed a break than the patients in the treatment arm (P = 0.034[T1]).


Conclusions: The two Dead Sea products tested decreased skin and mucosal toxicity in head and neck cancer patients receiving radiochemotherapy.


 

Download PDF Print
Legal Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal or medical advice on any matter.
The IMA is not responsible for and expressly disclaims liability for damages of any kind arising from the use of or reliance on information contained within the site.
© All rights to information on this site are reserved and are the property of the Israeli Medical Association. Privacy policy

2 Twin Towers, 35 Jabotinsky, POB 3566, Ramat Gan 5213604 Israel